Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2′,2′-difluorodeoxyuridine and their nucleotides

The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

(2017) Simon D Harding et al.   NUCLEIC ACIDS RESEARCH

Pharmacological factors affecting accumulation of gemcitabine’s active metabolite, gemcitabine triphosphate

(2017) Ivana Rizzuto et al.   PHARMACOGENOMICS

Inhibition of thymidylate synthase by 2′,2′-difluoro-2′-deoxycytidine (Gemcitabine) and its metabolite 2′,2′-difluoro-2′-deoxyuridine

(2015) Richard J. Honeywell et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer

(2015) R. van der Noll et al.   INVESTIGATIONAL NEW DRUGS

Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061

(2015) Linda Cerbone et al.   ONCOLOGY

Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer

(2014) Lucas de Sousa Cavalcante et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Correction of peripheral blood mononuclear cell cytosolic protein for hemoglobin contamination

(2013) Dick Pluim et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen

(2013) Cindy Serdjebi et al.   PHARMACOGENOMICS

Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients

(2011) C. Tibaldi et al.   ANNALS OF ONCOLOGY

Evaluation of the Mean Corpuscular Volume of Peripheral Blood Mononuclear Cells of HIV Patients by a Coulter Counter To Determine Intracellular Drug Concentrations

(2011) Marco Simiele et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors

(2011) B. Schultheis et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The Deaminated Metabolite of Gemcitabine, 2',2'-Difluorodeoxyuridine, Modulates the Rate of Gemcitabine Transport and Intracellular Phosphorylation via Deoxycytidine Kinase

(2011) L. S. Hodge et al.   DRUG METABOLISM AND DISPOSITION

Clinical pharmacology and pharmacogenetics of gemcitabine

(2009) Andrea Wong et al.   DRUG METABOLISM REVIEWS

Retention studies of 2′-2′-difluorodeoxycytidine and 2′-2′-difluorodeoxyuridine nucleosides and nucleotides on porous graphitic carbon: Development of a liquid chromatography–tandem mass spectrometry method

(2009) Robert S. Jansen et al.   JOURNAL OF CHROMATOGRAPHY A

Cytidine Deaminase Residual Activity in Serum Is a Predictive Marker of Early Severe Toxicities in Adults After Gemcitabine-Based Chemotherapies

(2009) Joseph Ciccolini et al.   JOURNAL OF CLINICAL ONCOLOGY

Simultaneous quantification of 2′,2′-difluorodeoxycytidine and 2′,2′-difluorodeoxyuridine nucleosides and nucleotides in white blood cells using porous graphitic carbon chromatography coupled with tandem mass spectrometry

(2009) Robert S. Jansen et al.   RAPID COMMUNICATIONS IN MASS SPECTROMETRY

Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients

(2008) C. Tibaldi et al.   CLINICAL CANCER RESEARCH

New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine

(2008) S. A. Veltkamp et al.   MOLECULAR CANCER THERAPEUTICS